Arrays for Point-of-Care Early Cancer Detection James F. Rusling Departments of Chemistry & Cell Biology University of Connecticut and UCHC Storrs, CT,

Slides:

Advertisements

Similar presentations

Ancha Baranova George Mason University, Fairfax, VA

Advertisements

Non Specific Binding (NSB) in Antigen-Antibody Assays Chem 395 Spring 2007 Instructor : Dr. James Rusling Presenter : Bhaskara V. Chikkaveeraiah.

Circulating Tumor Cells

16 November 2004Biomedical Imaging BMEN Biomedical Imaging of the Future Alvin T. Yeh Department of Biomedical Engineering Texas A&M University.

Protein Microarrays for Cancer Biomarkers Presenter: Naimish Sardesai Course: Bioanalytical Chemistry Date: 02/27/07 Instructor: Dr. James Rusling.

Bindley Bioscience Center Vision: Nurture interactive communication and interdisciplinary discovery with flexible laboratory project spaces and an open.

Microarrays: Tools for Proteomics

ELECTROCHEMICAL BIOSENSORS Modern and future approaches to medical diagnostics J. F. Rusling Dept. of Chemistry Dept. of Pharmacology, Univ. of CT Health.

1 Masterseminar „A statistical framework for the diagnostic of meningioma cancer“ Chair for Bioinformatics, Saarland University Andreas Keller Supervised.

Clinical Perspective. Screening/Prevention Who is at risk for what type Decision to Intervene: Risk Assessment normal Evidence of Disease Disability Death.

BLOOD TYPING LAB

Biosensor Array Strategies for Cancer Biomarker Proteins James F. Rusling Professor of Chemistry and Cell Biology University of Connecticut and University.

BIOC 401. Blood Sample To Detect Breast Cancer Cancer is actually a group of many related diseases that all have to do with cells. Cells are the very.

Lecture 4. Special chemistry Definition Special Chemistry is a subsection of the Chemistry Laboratory of the Division of Clinical Pathology. This includes.

Protein arrays LEAPS technology An array of 110 different antibodies incubated with various levels of the fluorescently labelled cognate antigens in a.

Objective DNA amplification (eg. PCR)    advances in forensic, clinical applications Comparable protein amplification tools (?)  aid medical diagnostics,

KEY CONCEPT Genetics provides a basis for new medical treatments.

Eleni Galani Medical Oncologist

Fundeni Centre for Immunogenetics & Virology

Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases J.M. Escudero,

EPCA: A silver lining for early diagnosis of prostate cancer GHOLAMREZA POURMAND, MD Professor of Urology Urology Research Center Tehran University of.

Mitosis & Cancer: When Making New Cells Goes Terribly Wrong!

The Need for Organ Site Specific Cancer Research John T Isaacs Chemical Therapeutic Program Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

False Biomarker Discovery due to Reactivity of a Commercial ELISA for CUZD1 with Cancer Antigen CA125 I. Prassas, D. Brinc, S. Farkona, F. Leung, A. Dimitromanolakis,

Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012.

Tumor markers Present; by Dr. Andalib Isfahan Medical School

Biochemical markers in disease diagnosis

OnSite PSA Rapid Test. Prostate glance What is prostate? A gland in the male reproductive system reproductive system.

When will the diagnosis of Circulating tumor cells (CTC) help to patients? Martin Pešta, Ondřej Topolčan Department of Internal Medicine II, Faculty of.

ELISA Assay. What Is It? Enzyme immunoassay (EIA) is a test used to detect and quantify specific antigen-eliciting molecules involved in biological processes,

Gene Therapy AP Biology Unit 2 + What is Gene Therapy? A way to treat or cure diseases by inserting the “correct” DNA into the cell. Most promising for.

CA-125 Cancer Antigen-125 Discovered in l981

The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Fifth Annual African-American Prostate Cancer Disparity Summit September 24, 2009 Christine.

©Edited by Mingrui Zhang, CS Department, Winona State University, 2008 Identifying Lung Cancer Risks.

Engr College of Engineering Engineering Education Innovation Center Engr 1182 Nano Pre-Lab Intro to Lab-on-a-chip Rev: 20XXMMDD, InitialsPresentation.

Andrew Attia, Miriam Bishay & Carly Sterling September 15, 2015 Diagnostic Blood Testing PHM142 Fall 2015 Instructor: Dr. Jeffrey Henderson.

Differential Protein Expression Analysis for Biomarker Discovery.

High throughput Protein Measurement Techniques Harin Kanani.

Dissect the plasma protein markers for Parkinson’s disease Wang Vin-Chi, Lin Ching-Yu, and Chen Han-Min.

BINDING KINETICS OF FREE- AND TOTAL-PROSTATE SPECIFIC ANTIGEN USING FRACTAL ANALYSIS ATUL M. DOKE AND AJIT SADANA CHEMICAL ENGINEERING DEPARTMENT AND COMPOSITE.

Author: Cheng-Chi Wang, Chi-Huey Wong

KEY CONCEPT Genetics provides a basis for new medical _____________.

Biochemical markers for diagnosis of diseases and follow up Dr. Rana Hasanato Associate professor and consultant Head of clinical chemistry department.

Per-Anders Abrahamsson, Department of Urology Malmö University Hospital Sweden EAU, Berlin, March 24, 2007 What´s New in Prostate Cancer?

Biochemical markers for diagnosis and follow up of disease

Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood Jenny Zhou and Anne Ye Fan, Vermesh, et.

Magnetically Promoted Rapid Immunoreactions Using Functionalized Fluorescent Magnetic Beads Satoshi Sakamoto and Co Department of Biological Information.

Unit 6: Tumor markers. Introduction… Cancer is the second leading cause of death in North America, accounting for > 2.7 million deaths annually Although.

Lab-on-a-Chip The Ideal Technology for Bio-chemical Analysis

Standad and Novel Biomarkers for Ovarian Cancer 최문선 ∙ 정희윤 1.

Products > PC-3 Transfection Reagent (Prostate Cancer Cells) Altogen Biosystems offers the PC-3 Transfection Reagent among a host of 100+ cell line specific.

Odor-based Sensors for Ovarian Cancer Detection

Tumor markers 1111.

The tNASP protein, a novel diagnostic biomarker for prostate cancer?

Fluorescence intensity

Nat. Rev. Urol. doi: /nrurol

SD Malaria P.f/P.v Antigen Test STANDARD DIAGNOSTICS, INC.

biochemical markers for diagnosis and follow up of diseases

Other chronic diseases Neurodegenerative diseases

KEY CONCEPT Genetics provides a basis for new medical treatments.

Nat. Rev. Urol. doi: /nrurol

Feline Blood Typing The only automated blood typing test for your cat

KEY CONCEPT Genetics provides a basis for new medical treatments.

KEY CONCEPT Genetics provides a basis for new medical treatments.

HEALTHSENS, S.L. PAMPLONA, SEPTEMBER 29th.

KEY CONCEPT Genetics provides a basis for new medical treatments.

KEY CONCEPT Genetics provides a basis for new medical treatments.

Biochemical markers for diagnosis of diseases and follow up

KEY CONCEPT Genetics provides a basis for new medical treatments.

PSMA expression in pre- and posttreatment prostate carcinoma serum.

Presentation transcript:

Arrays for Point-of-Care Early Cancer Detection James F. Rusling Departments of Chemistry & Cell Biology University of Connecticut and UCHC Storrs, CT, USA

Detecting cancer through protein biomarkers Early cancer detection holds great promise for preventive therapies to avoid cancer. Cancer biomarkers are biomolecules (proteins) expressed in cancer and cancer-risk situations. Measurement of collections of protein cancer biomarkers provides reliable diagnostics (~99% correct) Genetic cancer markers important for full picture

The Grand Challenge Inexpensive point-of-care biosensor arrays for cancer biomarker screening automated, easy to use and interpret measure several hundred biomarkers in several drops of patient serum achieve effective cancer prevention for millions lead to new mechanism-based therapies

Example: 4 Prostate Cancer Biomarkers Prostate Specific Antigen (PSA)  glycoprotein MW 33 kD  PSA in serum: clinical method for detecting prostate cancer  4-10 ng/mL up to 5 years before clinical signs of disease PF4 – Platelet Factor 4 –Normal conc. in human plasma 2-10 ng/mL, early cancer>10 ng/mL MMP-2 – Matrix Metalloproteinase 2 –zinc dependant proteinase; 3 enhances tumor growth; human plasma conc. normal < 300 ng/mL; cancer ng/mL PSMA - Prostate Specific Membrane Antigen –overexpressed in high grade prostate cancer; –human plasma conc. normal < 250 ng/mL; cancer ng/mL

One approach - electrochemical sandwich immunoassays nanostructured electrodes multi-label detection; ultralow NSB

The Dream Microfluidic system interfaced to multi-element Chip for sample, reagent, & wash automation. User need only add sample Interfaced laptop provides data analysis, database comparisons, interpreted results, transmittal to physicians. Multielectrode Chip - many capture antibodies